Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 8—August 2004


Pharmacy Data for Tuberculosis Surveillance and Assessment of Patient Management

Deborah S. Yokoe*Comments to Author , Steven W. Coon†, Rachel Dokholyan‡, Michael C. Iannuzzi†, Timothy F. Jones§, Sarah Meredith¶, Marisa Moore#, Lynelle Phillips**, Wayne Ray¶, Stephanie Schech††, Deborah Shatin††, and Richard Platt*†‡‡
Author affiliations: *Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; †Henry Ford Health System, Detroit, Michigan, USA; ‡Harvard Pilgrim Health Care, Boston, Massachusetts, USA; §Tennessee Department of Health, Nashville, Tennessee, USA; ¶Center for Education and Research in Therapeutics and Vanderbilt University, Nashville, Tennessee, USA; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **Missouri Department of Health and Senior Services, Jefferson City, Missouri, USA; ††Center for Health Care Policy and Evaluation, Minneapolis, Minnesota, USA; and; ‡‡HMO Research Network Center for Education and Research on Therapeutics, Boston, Massachusetts, USA

Main Article

Table 1

Identification of tuberculosis (TB) cases by using pharmacy screening

Cases Plan A (%) Plan B (%) Plan C (%) Total (%)
Total no. dispensed 2 or more anti-TB drugs 73 28 143 244
Matched to TB registry (previously reported TB cases) 12 (17) 6 (21) 43 (30) 61 (25)
Previously unreported TB cases (verified by record review) 3 (4) 1 (4) 9 (6)a 13 (5)
Not a TB case (verified by record review) 55 (75) 7 (25) 91 (64) 153 (63)
Case status not determined 3 (4) 14 (50) 0 17 (7)

aIncludes two cases not found in the state health department’s TB registry but reported to other state health departments.

Main Article